Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5759587 | 1.00 | HTR1A (0.47) | HTR1ASLC6A4CA2 | |
| SCHEMBL6314181 | 1.00 | HTR1A (0.47) | HTR1ASLC6A4CA2 | |
| SCHEMBL7118568 | 1.00 | HTR1A (0.47) | HTR1ASLC6A4CA2 | |
| SCHEMBL5760790 | 1.00 | HTR1A (0.47) | HTR1ASLC6A4CA2 | |
| SCHEMBL7505264 | 1.00 | HTR1A (0.47) | HTR1ASLC6A4CA2 | |
| SCHEMBL5762725 | 0.85 | HTR2C (0.51) | HTR1ASLC6A4CA2 | |
| Hydrochloric Acid SCHEMBL7095913 | 0.84 | HTR2C (0.52) | HTR1ASLC6A4CA2 | |
| SCHEMBL5758589 | 0.84 | HTR1A (0.41) | HTR1ASLC6A4 | |
| SCHEMBL5758594 | 0.84 | HTR1A (0.41) | HTR1ASLC6A4 | |
| SCHEMBL5760366 | 0.84 | HTR1A (0.41) | HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6844344-B2 | Benzofuran derivatives | ELI LILLY AND COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
| US-20030232833-A1 | Benzofuran derivatives | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1246822-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001046177-A1 | BENZOFURAN DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | IDO1, TPH1, IDO2 | HTR1A 4/4885SLC6A4 45/4885CA2 3251/4885 |
| US-20030232833-A1 | Benzofuran derivatives | BRD1, BPTF, HTR1F | HTR1A 8/4885SLC6A4 227/4885CA2 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.